Home > Cannabis-based medicinal products.

National Institute for Health and Care Excellence. (2021) Cannabis-based medicinal products. London: NICE. NICE guideline [NG144].

PDF (Cannabis-based medicinal products - guidance. November 2019)
PDF (Cannabis-based medicinal products: clarification of guidance - March 2021) - Supplemental Material

External website: https://www.nice.org.uk/guidance/NG144

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.



This guideline includes recommendations on:

 Products covered by the guideline include:

  • cannabis-based products for medicinal use as set out by the UK Government in the 2018 Regulations
  • the licensed products delta-9-tetrahydrocannibinol combined with cannabidiol (Sativex) and nabilone
  • plant-derived cannabinoids such as pure cannabidiol (CBD)
  • synthetic compounds which are identical in structure to naturally occurring cannabinoids such as delta-9-tetrahydrocannabinol (THC), for example, dronabinol.

Repository Staff Only: item control page